Acorda to Present at the 34th Annual J.P. Morgan Healthcare Conference
December 22 2015 - 11:11AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will
present at the 34th Annual J.P. Morgan Healthcare Conference in San
Francisco on Monday, January 11, 2016 at 10:30 a.m. PST/1:30 p.m.
EST.
A live audio webcast of the presentation can be accessed under
“Investor Events” in the Investor section of the Acorda website at
www.acorda.com, or you may use the link:
http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19772
Please log in approximately 5 minutes before the scheduled time
of the presentations to ensure a timely connection. An archived
version of this webcast will be available until February 11, 2016
on the Investors section of www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company
focused on developing therapies that restore function and improve
the lives of people with neurological disorders.
Acorda markets three FDA-approved therapies, including
AMPYRA®(dalfampridine) Extended Release Tablets, 10 mg. The Company
has one of the leading pipelines in the industry of novel
neurological therapies. Acorda is currently developing a number of
clinical and preclinical stage therapies. This pipeline addresses a
range of disorders including post-stroke walking deficits,
Parkinson’s disease, epilepsy, heart failure, MS and spinal cord
injury.
For more information, please visit the Company’s website at:
www.acorda.com.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or
prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including the ability to realize the
benefits anticipated from the Civitas transaction and to
successfully integrate Civitas' operations into our operations; our
ability to successfully market and sell Ampyra in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz (diazepam) Nasal
Spray, or any other acquired or in-licensed programs; we may not be
able to complete development of, obtain regulatory approval for, or
successfully market CVT-301, Plumiaz, or any other products under
development; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable
terms; the occurrence of adverse safety events with our products;
delays in obtaining or failure to obtain regulatory approval of or
to successfully market Fampyra outside of the U.S. and our
dependence on our collaboration partner Biogen International GmbH
in connection therewith; competition; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and,
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this release are made only as of the date hereof, and Acorda
disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151222005064/en/
Acorda TherapeuticsFelicia Vonella,
914-326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024